Earnings Update: Optomed Oyj (HEL:OPTOMED) Just Reported And Analysts Are Trimming Their Forecasts

Last week saw the newest quarterly earnings release from Optomed Oyj (HEL:OPTOMED), an important milestone in the company's journey to build a stronger business. Revenue of €4.4m came in 2.7% ahead of expectations, although statutory earnings didn't fare nearly so well, recording a loss of €0.08, a 14% miss. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the most recent consensus for Optomed Oyj from three analysts is for revenues of €21.4m in 2026. If met, it would imply a huge 23% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 40% to €0.17. Before this earnings announcement, the analysts had been modelling revenues of €23.7m and losses of €0.17 per share in 2026.

View our latest analysis for Optomed Oyj

The consensus price target was broadly unchanged at €4.80, implying that the business is performing roughly in line with expectations, despite a downwards adjustment to forecast revenue next year. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Optomed Oyj, with the most bullish analyst valuing it at €5.20 and the most bearish at €4.20 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Optomed Oyj is an easy business to forecast or the the analysts are all using similar assumptions.

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Optomed Oyj's past performance and to peers in the same industry. The analysts are definitely expecting Optomed Oyj's growth to accelerate, with the forecast 18% annualised growth to the end of 2026 ranking favourably alongside historical growth of 2.6% per annum over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 7.0% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Optomed Oyj to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Regrettably, they also downgraded their revenue estimates, but the latest forecasts still imply the business will grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Optomed Oyj. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Optomed Oyj analysts - going out to 2027, and you can see them free on our platform here.

You should always think about risks though. Case in point, we've spotted 1 warning sign for Optomed Oyj you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.